Tokyo - Delayed Quote JPY

Daiken Medical Co., Ltd. (7775.T)

442.00
-2.00
(-0.45%)
At close: 3:30:00 PM GMT+9
Loading Chart for 7775.T
  • Previous Close 444.00
  • Open 444.00
  • Bid 442.00 x --
  • Ask 443.00 x --
  • Day's Range 441.00 - 444.00
  • 52 Week Range 438.00 - 555.00
  • Volume 30,600
  • Avg. Volume 58,164
  • Market Cap (intraday) 12.698B
  • Beta (5Y Monthly) 0.03
  • PE Ratio (TTM) 11.98
  • EPS (TTM) 36.90
  • Earnings Date Jul 29, 2025 - Aug 4, 2025
  • Forward Dividend & Yield 20.00 (4.50%)
  • Ex-Dividend Date Sep 29, 2025
  • 1y Target Est 950.00

Daiken Medical Co., Ltd. engages in the manufacture and distribution of medical devices and equipment in Japan and internationally. The company offers suction devices; balloon type and syringe type disposable infusion pumps; endobronchial blocker tubes; and wet disinfectant mats. It is also involved in trading of medical equipment. The company sells its products under the COOPDECH brand name. Daiken Medical Co., Ltd. was incorporated in 1968 and is headquartered in Izumi, Japan.

daiken-iki.co.jp

--

Full Time Employees

March 31

Fiscal Year Ends

Recent News: 7775.T

View More

Performance Overview: 7775.T

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is Nikkei 225 (^N225) .

YTD Return

7775.T
12.92%
Nikkei 225 (^N225)
6.85%

1-Year Return

7775.T
15.16%
Nikkei 225 (^N225)
4.97%

3-Year Return

7775.T
1.48%
Nikkei 225 (^N225)
37.62%

5-Year Return

7775.T
11.61%
Nikkei 225 (^N225)
82.26%

Compare To: 7775.T

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 7775.T

View More

Valuation Measures

Annual
As of 5/22/2025
  • Market Cap

    12.76B

  • Enterprise Value

    12.06B

  • Trailing P/E

    12.04

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.30

  • Price/Book (mrq)

    1.75

  • Enterprise Value/Revenue

    1.23

  • Enterprise Value/EBITDA

    6.88

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.02%

  • Return on Assets (ttm)

    8.52%

  • Return on Equity (ttm)

    15.09%

  • Revenue (ttm)

    9.95B

  • Net Income Avi to Common (ttm)

    1.1B

  • Diluted EPS (ttm)

    36.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3B

  • Total Debt/Equity (mrq)

    27.29%

  • Levered Free Cash Flow (ttm)

    776.37M

Research Analysis: 7775.T

View More

Company Insights: 7775.T

Research Reports: 7775.T

View More

People Also Watch